Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors

NCT ID: NCT00893945

Last Updated: 2014-12-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-06-30
• Study Completion Date: 2013-12-31

Brief Summary

This study involves cancer research and the purpose is to assess the safety and activity of a type of vaccine as immune therapy for cancer.

This vaccine will be made from each participant's own immune cells (called dendritic cells) obtained by blood donation. Dendritic cells (DCs) are immune cells whose role is to identify foreign material in the body (such as bacteria, viruses, or tumor cells).

When DCs recognize this material, they use it to activate other cells of the immune system to mount an attack against that foreign material. In the Laboratory of Molecular Neuro-Oncology, each participant's DCs will be loaded with samples of their own tumor cells that were obtained at surgical resection. These tumor cells are killed in the laboratory using a special protocol, and then "fed" to the DCs. The DCs "eat" this material, and these "fed" DCs make up the vaccine.

Detailed Description

If you are eligible, and you decide to join this research study, you will get two to three shots of the experimental vaccine, each three weeks apart.

You will then have a follow up period where we will monitor you and your medical records for any affects of the experimental treatment.

Conditions

Brain Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

DC/AAT vaccine

Intradermal injection of 3 Autologous dendritic cell vaccines (DC/AAT, DC/AAT-flu, DC/KLH) that have been co-cultured with autologous apoptotic tumor specimens.

Group Type: EXPERIMENTAL

DC/AAT

Intervention Type: DRUG

Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.

DC/AAT-Flu

Intervention Type: DRUG

Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT

DC/KLH

Intervention Type: DRUG

Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.

Interventions

DC/AAT

Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.

Intervention Type: DRUG

DC/AAT-Flu

Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT

Intervention Type: DRUG

DC/KLH

Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.

Intervention Type: DRUG

Other Intervention Names

Dendritic cell/autologous apoptotic tumor; dendritic cell/flu-infected autologous apoptotic tumor; dendritic cell/Keyhole Limplet hemocyanin

Eligibility Criteria

Inclusion Criteria

Screening to determine eligibility (with the exception of HLA haplotyping) will be completed within 45 days fo study entry.

1. Disease Characteristics

Histologically confirmed brain cancers, reviewed at MSKCC. Pathologic examination will be of surgical resection specimens deemed of suitable quality for definitive diagnosis by the histopathologist.

Primary Brain Tumors:

• Anaplastic astrocytoma
• Glioblastoma multiforme
• Anaplastic oligodendroglioma
• Malignant mixed oligoastrocytoma

Secondary (metastatic) brain tumors - newly diagnosed or recurrent disease

• All histological grade of disease accepted

Surgically accessible tumor for which resection is indicated. Tumors may be from initial resections or re-resections. Recovery of a minimum of 1x10^7 tumor cells ex vivo is required.

Patients with primary brain tumors must have been previously treated with conventional therapy.

2. Prior/Concurrent Therapy

1. Recovered from toxicity of any prior therapy

2. Biologic Therapy

• No concurrent other immunotherapy and no prior immunotherapy with any of the components of the current regimen (autologous DCs, cancer cells, or KLH)

3. Chemotherapy:

• No concurrent immunomodulatory or chemotherapy therapy
• Chemotherapy, including temozolomide and local chemotherapies such as Gliadel Wafers, must be deferred until after last post-vaccine leukapheresis

4. Endocrine evaluation/therapy:

• steroid dose no greater than 1mg daily dexamethasone (or equivalent)

5. Radiotherapy:

• No concurrent brain radiation

6. Surgery:

• Surgical resection must have been completed independently of this study, and suitable samples obtained for vaccine production

3. Patient Characteristics

1. Age: 18 and over, able to give written informed consent. May be obtained through use of legal representation such as a health care proxy

2. Performance status: Karnofsky 60-100%

3. Life expectancy: at least 4-6 months

4. Hematopoietic:

• WBC greater than 3,800
• Absolute lymphocytes greater than 500
• Absolute neutrophil counter great than 1,500/mm^3
• Platelets greater than 100,000/mm^3
• Hb greater than or equal to 10g/dL

5. Hepatic: bilirubin less than 2mg/dL OR SGOT less than 2x ULN

6. Renal: Creatinine no greater than 2mg/dL

7. Cardiovascular:

• No NYHA class III/IV status
• No active angina, uncontrolled clinically significant cardiac arrythmia, recent (6 months) myocardial infarction

8. Pulmonary: No symptomatic pulmonary disease or pulse oximetry less than 93% on room air

9. Endocrine: No history of autoimmune thyroid disease

10. Radiographic: baseline contrast-enhanced MRI or CT scan of brain post surgical resection

11. Coagulation: No unexplained INR >2

Exclusion Criteria

• No active infection requiring antibiotics
• No history of HIV, hepatitis B or hepatitis C virus infection, no history of high risk behavior for such infection (intravenous drug abuse, men having unprotected sex with men). Laboratory evaluation for HIV, hepatitis B, hepatitis C to be obtained prior to study entry
• No history of hypersensitivity to vaccine components
• No history of autoimmune or vasculitic disease (including but not limited to systemic lupus erythematosis, Hashimoto's thyroiditis, rheumatoid arthritis, systemic necrotizing vasculitides (polyarteritis nodosa group), hypersensitivity vasculitis, Wegener's granulomatosis), scleroderma, multiple sclerosis, juvenile-onset insulin-dependent diabetes
• No medical or psychiatric illness or social condition that, in the opinion of the investigator, would interfere with adherence to study requirements
• No alcohol or drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role: collaborator

Rockefeller University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Robert Darnell, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Rockefeller University

Locations

Rockefeller University

New York, New York, United States

Countries

United States

References

Frank MO, Kaufman J, Parveen S, Blachere NE, Orange DE, Darnell RB. Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer. J Transl Med. 2014 Dec 5;12:338. doi: 10.1186/s12967-014-0338-3.

Reference Type: DERIVED

PMID: 25475068 (View on PubMed)

Other Identifiers

RDA-0611

Identifier Type: -

Identifier Source: org_study_id